HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.

Abstract
Alum, the only adjuvant approved for clinical applications, can induce strong humoral (Th2) but weak cellular (Th1) immune responses. It is necessary to develop safe and effective adjuvants capable of inducing both humoral and cellular immune responses. We previously showed that activation-associated protein-1 (ASP-1) derived from Onchocerca volvulus has potent adjuvant activity. In this study, we have further evaluated the adjuvanticity of recombinant ASP-1 using a panel of recombinant proteins or synthetic peptide-based antigens, including ovalbumin (OVA), synthetic HIV peptide (HIV-p), recombinant HIV gp41 (rgp41) and HBV HBsAg, as well as three commercially available inactivated vaccines against haemorrhagic fever with renal syndrome (HFRS), Influenza and Rabies. Our results indicate that ASP-1 induced significantly higher IgG1 (Th2-associated) and IgG2a (Th1-associated) responses than alum adjuvant against OVA antigen, HIV-p, and rgp41. Consistently, it induced similar level of IgG1 responses as alum but higher level of IgG2a and IFN-gamma-producing T cell responses than alum adjuvant against HBsAg. Further, ASP-1 improved both IgG1 and IgG2a responses to three commercial inactivated vaccines when used separately or in combination. In conclusion, the recombinant ASP-1, unlike alum adjuvant, is able to induce both Th1 and Th2-associated humoral responses and Th1 cellular responses, suggesting that it can be further developed as a promising adjuvant for subunit-based and inactivated vaccines.
AuthorsWenjun Xiao, Lanying Du, Chao Liang, Jie Guan, Shibo Jiang, Sara Lustigman, Yuxian He, Yusen Zhou
JournalVaccine (Vaccine) Vol. 26 Issue 39 Pg. 5022-9 (Sep 15 2008) ISSN: 0264-410X [Print] Netherlands
PMID18675867 (Publication Type: Comparative Study, Evaluation Studies, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Alum Compounds
  • Antibodies, Viral
  • HIV Envelope Protein gp41
  • Helminth Proteins
  • Hepatitis B Surface Antigens
  • Immunoglobulin G
  • Recombinant Proteins
  • Vaccines, Inactivated
  • Vaccines, Synthetic
  • Viral Vaccines
  • aluminum sulfate
  • Ovalbumin
Topics
  • Adjuvants, Immunologic (pharmacology)
  • Alum Compounds (pharmacology)
  • Animals
  • Antibodies, Viral (immunology)
  • HIV (immunology)
  • HIV Envelope Protein gp41 (immunology)
  • Helminth Proteins (immunology)
  • Hepatitis B Surface Antigens (immunology)
  • Hepatitis B virus (immunology)
  • Immunoglobulin G (immunology)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Onchocerca volvulus (immunology)
  • Ovalbumin (immunology, pharmacology)
  • Recombinant Proteins (immunology)
  • Th1 Cells (immunology)
  • Vaccines, Inactivated (immunology)
  • Vaccines, Synthetic (immunology)
  • Viral Vaccines (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: